Long acting GLP-1 receptor agonist (injectable)
Dulaglutide injection
DULA_SC
Doses in this pooled treatment
- Dulaglutide 1.0 mg injection once weekly
- Dulaglutide 1.5 mg subcutaneous once weekly
- Dulaglutide 3.0 mg subcutaneous once weekly
- Dulaglutide 4.5 mg subcutaneous once weekly
- Dulaglutide 0.25 mg injection once weekly
- Dulaglutide 0.5 mg injection once weekly
- Dulaglutide 0.75 mg subcutaneous once weekly
- Dulaglutide flexible dose injection once weekly
- Dulaglutide 2.0 mg injection once weekly
- Dulaglutide 0.1 mg injection once weekly
- Dulaglutide 0.75 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.07 (-1.32 to -0.82) | 0.68 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.04 (-1.33 to -0.73) | 0.68 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.32 (-1.36 to 0.84) | 0.53 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.15 (-1.87 to 0.24) | 0.52 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.14 (-1.88 to -0.19) | 0.82 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.58 (-2.20 to -0.68) | 0.89 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.77 (-1.28 to -0.20) | 0.50 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.41 (-2.36 to 0.35) | 0.77 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.76 (-1.42 to -0.02) | 0.44 |
| Type 2 diabetes (adults) | HbA1c change | weeks 64 to 130 (target week 104) | Insulin glargine | MD -0.17 (-1.12 to 0.86) | 0.60 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.19 (-2.03 to -0.41) | 0.43 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.55 (-6.30 to 3.95) | 0.58 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.66 (-2.25 to 0.89) | 0.61 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.53 (-5.11 to 2.29) | 0.37 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.54 (-5.62 to 3.17) | 0.40 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.28 (-3.97 to 1.71) | 0.39 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.32 (-6.93 to 2.35) | 0.66 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.60 (-2.30 to 3.50) | 0.22 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 64 to 130 (target week 104) | Insulin glargine | MD -2.96 (-7.54 to 2.28) | 0.58 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 11.88 (3.89 to 24.98) | 0.72 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Semaglutide injection | OR 0.53 (0.19 to 1.55) | 0.48 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 5.64 (0.81 to 19.38) | 0.71 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 4.74 (0.57 to 21.33) | 0.62 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 8.08 (3.58 to 17.15) | 0.78 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 9.18 (1.02 to 35.81) | 0.75 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 16.93 (2.65 to 73.24) | 0.80 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 5.93 (0.63 to 29.26) | 0.66 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.17 (0.04 to 0.53) | 0.61 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.95 (1.05 to 3.60) | 0.61 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.03 (0.57 to 1.75) | 0.70 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.38 (0.14 to 0.93) | 0.78 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.00 (-3.16 to -0.75) | 0.54 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 1.16 (-2.67 to 6.60) | 0.40 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -1.06 (-6.44 to 3.56) | 0.38 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -3.78 (-15.29 to 9.14) | 0.71 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -3.74 (-20.06 to 14.11) | 0.61 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -0.24 (-6.29 to 5.64) | 0.51 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -0.91 (-15.86 to 14.61) | 0.46 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -1.81 (-5.74 to 2.17) | 0.29 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 64 to 130 (target week 104) | Insulin glargine | MD -1.21 (-12.96 to 9.94) | 0.62 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Semaglutide tablet | MD 1.19 (-5.95 to 7.83) | 0.43 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -1.42 (-7.15 to 4.39) | 0.37 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -2.33 (-8.06 to 4.15) | 0.43 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -1.13 (-10.65 to 9.45) | 0.48 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 5.26 (1.41 to 18.88) | 0.58 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.11 (0.32 to 9.15) | 0.53 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.83 (0.24 to 9.03) | 0.35 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 1.77 (0.33 to 6.94) | 0.41 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.58 (0.38 to 9.65) | 0.31 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 5.24 (0.93 to 29.91) | 0.50 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 0.22 (0.00 to 4.22) | 0.09 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 2.18 (0.09 to 27.41) | 0.42 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 0.21 (0.00 to 3.97) | 0.08 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Semaglutide injection | OR 0.23 (0.09 to 0.76) | 0.24 |
| Type 2 diabetes (adults) | All cause mortality | longest follow-up | Placebo | HR 0.90 (0.58 to 1.38) | 0.47 |
| Type 2 diabetes (adults) | Three point MACE | longest follow-up | Placebo | HR 0.88 (0.50 to 1.50) | 0.47 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.40 (-1.45 to 2.16) | 0.58 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 1.09 (-2.37 to 4.74) | 0.68 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Semaglutide tablet | MD 0.54 (-6.53 to 8.44) | 0.60 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.88 (0.74 to 1.04) | 0.61 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.45 (0.95 to 2.19) | 0.49 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.85 (2.24 to 3.67) | 0.37 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.44 (1.81 to 3.32) | 0.44 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.72 (1.43 to 2.11) | 0.39 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.85 (1.47 to 2.38) | 0.38 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.63 (0.12 to 2.59) | 0.63 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 0.62 (0.02 to 16.52) | 0.55 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.65 (0.13 to 1.75) | 0.46 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 1.19 (0.49 to 2.49) | 0.50 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 1.36 (0.40 to 3.78) | 0.34 |
| Type 2 diabetes (adults) | Any cancer | longest follow-up | Placebo | HR 0.97 (0.27 to 2.60) | 0.65 |
| Children and adolescents with type 2 diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.36 (0.04 to 2.84) | 0.77 |
| Children and adolescents with type 2 diabetes | Nausea | longest follow-up | Placebo | HR 1.86 (0.43 to 9.01) | 0.38 |
| Children and adolescents with type 2 diabetes | Vomiting | longest follow-up | Placebo | HR 3.97 (0.80 to 23.92) | 0.30 |
| Children and adolescents with type 2 diabetes | Diarrhea | longest follow-up | Placebo | HR 1.38 (0.40 to 4.91) | 0.46 |
| Polycystic ovary syndrome | Nausea | longest follow-up | Standard care or no added treatment | HR 16.15 (1.64 to 331) | 0.02 |
| Polycystic ovary syndrome | Diarrhea | longest follow-up | Standard care or no added treatment | HR 0.52 (0.00 to 34.23) | 0.59 |
Trials
- S0030901 weeks
- SURPASS-SWITCHA Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes2022 · 282 randomized · 40 weeks
- NCT05407961A Phase 1b, 2-Part, Investigator- and Participant-Blind, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3532226 in Participants With Type 2 Diabetes Mellitus2022 · 72 randomized · 12 weeks
- NCT05048719A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus2021 · 383 randomized · 26 weeks
- NCT04965506A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes2021 · 252 randomized · 20 weeks
- NCT04867785A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes2021 · 281 randomized · 36 weeks
- NCT04876027Dulaglutide and Calorie Restrict Diet (CRD) in Overweight/Obese Patients With Polycystic Ovary Syndrome2021 · 68 randomized · 26.07 weeks
- S0030502020 · 60 randomized · 12 weeks
- S0029462020 · 32 randomized · 26 weeks
- NCT04466904A Multiple Dose Human Tolerability and Pharmacokinetic Study of IBI362 in Chinese Patients With Type 2 Diabetes Mellitus and Poor Glycemic Control2020 · 43 randomized · 12 weeks
- S0034422019 · 96 randomized · 24 weeks
- S0028852019 · 25 randomized · 12 weeks
- D-LIFTEffect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial2018 · 64 randomized · 24 weeks
- AWARD-11A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus2018 · 1,842 randomized · 52 weeks
- NCT03131687A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus2017 · 318 randomized · 26 weeks
- PIONEER 10Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD in Japanese Subjects With Type 2 Diabetes2017 · 458 randomized · 52 weeks
- NCT03824002Arterial Stiffness and Endothelial Function Indexes, Relationships With Clinical and Laboratory Variables in a Group of Diabetic Patients in Treatment With Dulaglutide: a Case-control Study2017 · 39.11 weeks
- SUSTAIN 7Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes2016 · 1,201 randomized · 40 weeks
- NCT02846233Is the Stepping-down Approach a Better Option Than Multiple Daily Injections in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?2016 · 22 randomized · 16 weeks
- AWARD-PEDSA Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)2016 · 154 randomized · 26 weeks
- AWARD-10A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus2015 · 424 randomized · 24 weeks
- AWARD-9A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg With Placebo on Glycemic Control in Patients With Type 2 Diabetes on Basal Insulin Glargine2014 · 300 randomized · 28 weeks
- AWARD-8A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8)2013 · 300 randomized · 24 weeks
- AWARD-CHN2The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea2012 · 774 randomized · 52 weeks
- NCT01558271A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus2012 · 492 randomized · 52 weeks
- AWARD-CHN1The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus2012 · 737 randomized · 26 weeks
- AWARD-6A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide With Once-Daily Liraglutide in Patients With Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation of LY2189265 in Diabetes-6)2012 · 599 randomized · 26 weeks
- NCT01584232A Phase 3 Study of LY2189265 Compared to Insulin Glargine in Patients With Type 2 Diabetes Mellitus on a Sulfonylurea and/or Biguanide2012 · 361 randomized · 26 weeks
- AWARD-7A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease2012 · 577 randomized · 52 weeks
- REWINDThe Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)2011 · 9,901 randomized
- AWARD-1A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)2010 · 978 randomized · 52 weeks
- AWARD-2A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride2010 · 810 randomized · 78 weeks
- NCT01191268The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)2010 · 884 randomized · 52 weeks
- NCT01149421The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus2010 · 755 randomized · 26 weeks
- NCT01126580The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)2010 · 807 randomized · 52 weeks
- NCT01001104Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Japanese Patients With Type 2 Diabetes2009 · 145 randomized · 12 weeks
- NCT00791479Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients With Type 2 Diabetes Treated Only With Lifestyle Interventions2008 · 167 randomized · 12 weeks
- EGOThe Effect of Dose Titration of LY2189265 in Overweight and Obese Patients With Type 2 Diabetes Mellitus2008 · 262 randomized · 16 weeks